Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015012 | 0.85 | SLC6A4 (0.54) | SLC6A4SLC6A3CYP3A4L3MBTL1KMT2A | |
| SCHEMBL1011495 | 0.85 | SLC6A4 (0.54) | SLC6A4SLC6A3CYP3A4L3MBTL1KMT2A | |
| SCHEMBL1010265 | 0.84 | FKBP1A (0.46) | SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1012738 | 0.83 | ALDH1A1 (0.46) | SLC6A4SLC6A3KCNH2KMT2A | |
| SCHEMBL7652967 | 0.83 | CYP2C19 (0.46) | SLC6A4SLC6A3CHRM2CYP3A4TSHR | |
| SCHEMBL1012334 | 0.82 | SLC6A4 (0.44) | SLC6A4SLC6A3L3MBTL1KMT2A | |
| SCHEMBL1011459 | 0.80 | SLC6A4 (0.42) | SLC6A4SLC6A3 | |
| SCHEMBL11097065 | 0.78 | SLC6A4 (0.48) | SLC6A4SLC6A3CHRM2KCNH2OPRK1 | |
| SCHEMBL11095157 | 0.78 | SLC6A4 (0.48) | SLC6A4SLC6A3CHRM2KCNH2OPRK1 | |
| SCHEMBL7243880 | 0.77 | AGTR2 (0.53) | CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-04-03 | — | — | US | disclosed |
| US-6486323-B1 | Process for producing optically active tropinonemonocarboxylic acid derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1118674-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | Nihon Medi-Physics Co., Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | CES2, FTO, HAAO | SLC6A4 1204/4885SLC6A3 712/4885CHRM2 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.